Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Glecaprevir/pibrentasvir Clear all
Completed Phase 2 Interventional Results available

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

NCT04042740
View directory record Official record
Conditions
Hepatitis C Infection, HIV Infection
Interventions
Glecaprevir/Pibrentasvir (G/P)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 4 Interventional Results available

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

NCT04515797
View directory record Official record
Conditions
Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions
Glecaprevir and Pibrentasvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

NCT03781726
View directory record Official record
Conditions
Renal Failure Chronic, Hepatitis C
Interventions
glecaprevir/pibrentasvir treatment
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

NCT03801707
View directory record Official record
Conditions
Kidney Transplant, Hepatitis C, HCV
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 24, 2026, 4:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

NCT07040319
View directory record Official record
Conditions
Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 4:02 PM EDT
Not listed Not applicable Interventional

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

NCT03164902
View directory record Official record
Conditions
Hepatitis C, Chronic, Nonadherence, Patient
Interventions
Digital Medicine
Device
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

NCT03092375
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

NCT04575896
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

NCT02966795
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients

NCT03117569
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
glecaprevir (300mg)/pibrentasvir (120mg)
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

HCV Test and Treat Utilizing Simplified HCV Patient Education

NCT05582681
View directory record Official record
Conditions
Hepatitis C
Interventions
Cepheid POC HCV Viremia (RNA) test, HCV education from a health care provider, Glecaprevir and Pibrentasvir
Diagnostic Test · Other · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Long Island City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

NCT02296905
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NCT04596475
View directory record Official record
Conditions
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions
glecaprevir/pibrentasvir (GLE/PIB)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 24, 2026, 4:02 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

NCT03702218
View directory record Official record
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 4 Interventional Results available

HCV Positive Heart Donors

NCT03382847
View directory record Official record
Conditions
Heart Failure
Interventions
Transplant with HCV positive donor, followed by surveillance and treatment of viremia
Combination Product
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

NCT03212521
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

NCT02442258
View directory record Official record
Conditions
Renal Impairment
Interventions
ABT-493, ABT-530
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 24, 2026, 4:02 PM EDT
Terminated Phase 4 Interventional Results available

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

NCT03625687
View directory record Official record
Conditions
Respiratory Failure, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 8 weeks
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

NCT02939989
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
8
States / cities
Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 24, 2026, 4:02 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

NCT04508907
View directory record Official record
Conditions
Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
Interventions
Mavyret
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

NCT03089944
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

NCT03069365
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
La Jolla, California • Pasadena, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 24, 2026, 4:02 PM EDT
Completed Early Phase 1 Interventional

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

NCT04682509
View directory record Official record
Conditions
ESRD
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 24, 2026, 4:02 PM EDT